pertactin


Also found in: Wikipedia.

per·tac·tin

(per-tak'tin),
The primary receptor of Bordetella pertussis, the antigenicity of which improves the effectiveness of pertussis vaccines.
[pertussis + act + -in]

per·tac·tin

(pĕr-tak'tin)
An antigenic material produced by Bordetella pertussis used to improve the effectiveness of pertussis vaccines.
[pertussis + act + -in]
References in periodicals archive ?
Changes have also been identified in Bordetella pertussis at the molecular level, such as loss of pertactin, a key aP vaccine antigen (3).
CDC biologist Lucia Pawloski and her colleagues screened 1,300 pertussis microbe samples collected from patients from 1935 to 2012 and found that 306 seemed unable to make pertactin.
Blood samples were measured for pertussis antigens, including pertussis toxoid, filamentous hemagglutinin, pertactin, and fimbriae, by enzyme-linked immunosorbent assay.
A substantial reduction in primary antibody response for all 10 pneumococcal conjugate vaccine serotypes and Hib polysaccharide, diphtheria, tetanus and pertactin antigens was found in the paracetamol group.
Royalties arise principally on Asacol, which is licensed to Proctor & Gamble in the USA and Canada, and Pertactin (69kDa) which is licensed to SmithKline Beecham for inclusion in their acellular pertussis vaccine, Infanrix (trademark of SmithKline Beecham).
One example is pertactin, a protein made by Bordetella pertussis, the bacterium responsible for whooping cough.
Although ACV formulations differ in the number of component pertussis antigens, the vaccine used in Australia contains pertussis toxin (Ptx), pertactin (Prn), and filamentous hemagglutinin (Fha).
Product royalties arise from North American sales of Asacol(R), a treatment for inflammatory bowel disorders, sold by Proctor & Gamble, Pertactin, licensed to GlaxoSmithKline, royalties arising from the Boss patent, initial royalties on sales of Mylotarg(TM) and Chirocaine(R).
ACEL-IMUNE has an acellular pertussis vaccine component with the following four antigens: agglutinogen (FIM 2), pertactin (PRN), filamentous hemagglutinin (FHA), and pertussis toxin (PT).
From per-(pertussis) + tactus (Latin, "to touch"), pertactin is a virulence factor of Bordetella pertussis that promotes adhesion to tracheal epithelial cells and resistance to neutrophil-mediated clearance and is a component of acellular pertussis vaccines.
Celltech Medeva royalties arise from US sales of Asacol(R), a treatment for inflammatory bowel disorders, sold by Proctor and Gamble, and Pertactin, licensed to SmithKline Beecham for acellular pertussis vaccines.
that has an acellular pertussis component with the following four antigens: agglutinogens (FIM), pertactin (PRN), filamentous hemagglutinin (FHA), and pertussis toxin (PT).